Obtain Real World Insights of Acquired Hemophilia A Patients in Japan2

Not Applicable

• Conditions: Acquired Hemophilia A

• Registration Number: JPRN-UMIN000047206
• Lead Sponsor: Chugai Pharmaceutical Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-03-17
• Study Completion: 2022-04-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

Patients for whom any of the following criteria apply will be excluded from this study. The entire observation period will apply for all criteria. 1)Patients assigned the receipt disease name, [antiphospholipid syndrome] (confirmed) 2)Patients assigned the receipt disease name, [lupus anticoagulant] (confirmed) 3)Patients assigned the receipt disease name, [acquired coagulation factor XIII deficiency] (confirmed) 4)Patients assigned the receipt disease name, [autoimmune acquired Von Willebrand's disease] (confirmed) 5)Patients assigned the receipt disease name, [acquired factor V deficiency] (confirmed) 6) Patients assigned the receipt idisease name [primary antiphospholipid antibody syndrome] (confirmed)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The following outcome measures will be set. In this study, the outcome measures will be analyzed for overall and each target segment (rehabilitation initiation time, period of immunosuppressant use, hospitalization period, ADL on discharge, hemorrhage, type of infection and Death). 1)Treatment implementation status A)Rehabilitation implementation status Type of rehabilitation, frequency, period up to initiation, duration of continuation 2)Outcome A)ADL on discharge

Secondary Outcome Measures

Name	Time	Method
The following outcome measures will be set. In this study, the outcome measures will be analyzed for overall and each target segment (rehabilitation initiation time, period of immunosuppressant use, hospitalization period, ADL on discharge, hemorrhage, type of infection and Death). 1)Epidemiology A)Age/sex B)Comorbidity disease 2)Treatment implementation status A)Use status of hemostatic agents Type of hemostatic agent, initial date of use, period of use B)Use status of immunosuppressants Type of immunosuppressant, amount used, period of use C)Hospitalization period 3) Outcome A)Hemorrhage B)Hospital transfer destination C)Infection D)Thromboembolism E)Death F)Nursing care level G)Dysphagia H)Bedsores I)Criteria for determining the level of independence in daily living for elderly persons with dementia